NCT02261376 - Effects of Age, Gender & Race on the Pharmacokinetics (PK)of DS-1971a | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Healthy

Interventions

DRUG

DS-1971a

DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research Ltd, London